Estuary Biotherapeutics Raises $93M for Kidney Gene Therapy

A small region of a very large protein gives Estuary Biotherapeutics a way to pursue a kidney gene therapy that would otherwise run into a packaging problem. The full PKD1 gene is too large for the AAV vector the company is using, so its developers are working with a functional region derived from the protein it encodes. That choice connects a Yale laboratory finding to the practical work now supported by a $93M Series A.

Estuary announced the financing on October 16, 2026, with RA Capital Management leading and total committed financing reaching $103M, including an earlier $10M seed. The Menlo Park, California, and Newton, Massachusetts, biotechnology company plans to advance 2 locally delivered genetic medicines for autosomal dominant polycystic kidney disease, or ADPKD, through clinical proof of concept. Investors are backing a development strategy in which getting the medicine into the kidney is central to what the company hopes to accomplish there.

What Estuary's $93M Series A will fund

The financing brings new investors together with the firms that backed Estuary's seed round. Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners and the National Kidney Foundation Innovation Fund participated, alongside a family office connected to an individual living with ADPKD. Seed co-leads 4BIO Capital and GV also returned for the Series A.

Estuary intends to use the proceeds for its lead programs, EST-201 and EST-101, and further development of its kidney-targeting platform. The announcement gives the investment a defined destination: clinical proof of concept for the lead medicines. It leaves valuation, investor allocations and cash runway undisclosed, so the headline amount offers no basis for calculating how the company has priced its eventual commercial opportunity.

For a research company, the return of early backers matters because the next phase asks different questions of the organization. A biological result has to become a reproducibly manufactured product, a workable administration procedure and a clinical program capable of producing interpretable evidence. Estuary has assembled capital around those connected tasks while its treatments are still investigational.

There is also a financing distinction worth retaining as the company becomes more visible. The $93M is the Series A; $103M is total committed financing across the Series A and seed. Treating the larger figure as a fresh round would obscure the earlier support that helped bring the programs to this stage.

Why the kidney delivery method matters

ADPKD causes fluid-filled cysts to develop and expand in the kidneys, damaging functioning tissue over time. Estuary's programs aim to address the inherited biology associated with mutations in PKD1 and PKD2. In its independent launch coverage, Fierce Biotech describes the company's plan to use local AAV delivery to reach kidney epithelial cells and restore polycystin protein levels.

EST-201 is designed to deliver a full-length PKD2 gene, with clinical entry targeted for 2027. EST-101 uses the same AAV approach to deliver a functional region derived from polycystin-1 for PKD1-related disease, with a 2028 target. Both dates are company expectations, and the potentially one-time administration remains an intended treatment design rather than established durability in patients.

The smaller payload has a specific scientific history. In a 2023 Nature Communications study, researchers found that expressing a short tail region of polycystin-1 suppressed cystic disease and preserved renal function in mouse models. Yale's account of that work explains why a compact functional region could make gene delivery more tractable than attempting to package the full gene.

For operators following the company, that relationship makes the administration route part of the development proposition. Estuary says the programs share a delivery approach and AAV features, creating an opportunity for learning across programs. How much clinical or manufacturing efficiency that common architecture produces will depend on the work conducted as each candidate advances.

The people carrying Yale biology into development

CEO and co-founder Wayne Sackett built Estuary with scientific co-founders Michael Caplan and Stefan Somlo, both at Yale, and gene therapy executive Xavier Anguela. The scientific foundation includes a 2021 Nature Genetics study showing that reactivating Pkd genes in mice could reverse features of established polycystic kidney disease. That result supports the biological rationale while leaving the task of delivering an effective medicine to people open.

The animal findings also make disease stage relevant to the interpretation. In its review of the research, the National Institute of Diabetes and Digestive and Kidney Diseases explains that later gene reactivation produced partial rather than complete reversal. A successful development program will need to establish what treatment can accomplish in the patients it actually enrolls.

Sackett's management team includes CSO Jeremy Duffield, CMO Uptal Patel, Christopher Morrison as SVP of CMC, and Kiley Keelin as Head of Regulatory. C&EN's launch reporting identifies those roles in its management-team coverage. Together, those functions place biological research alongside clinical development, manufacturing and regulatory work inside the same organization.

That mix is consequential for a company pursuing local administration. The delivery procedure, the product being delivered and the evidence used to evaluate the result have to be developed together. Investors and prospective partners will need to understand how those pieces fit when Estuary begins describing its clinical programs in greater detail.

ADPKD investment is moving across treatment approaches

Estuary enters a field drawing investment into several ways of addressing kidney disease biology. In April 2025, Novartis agreed to acquire Regulus Therapeutics for $800M upfront and up to $900M tied to a regulatory milestone, bringing the investigational microRNA-targeting medicine farabursen into its plans for ADPKD. Those terms describe an acquisition of a different program at a different stage, so they offer market context rather than a valuation comparison for Estuary.

The common commercial interest is in changing the course of a progressive disease. The development approaches carry their own delivery requirements, evidence histories and clinical questions. Estuary's position rests on bringing genetic cargo directly to kidney cells, with the goal of restoring the proteins implicated in disease formation.

The company's current website explicitly identifies its candidates as investigational and states that safety and efficacy have not been established. Local delivery is intended to address challenges associated with systemic AAV administration; the available evidence cannot establish a human safety advantage or a durable reversal of disease. Those distinctions will remain important as planned clinical-entry dates approach.

Estuary plans to take EST-201 into the clinic ahead of EST-101, putting the PKD2 program at the front of its kidney-delivery strategy. Sackett and his colleagues will be carrying the shared administration approach into programs with different genetic cargo. As that sequence develops, the company will be learning how much of its shared kidney-delivery approach can travel with the next genetic payload.